San Diego, CA. March 14, 2026 – Medical Affairs 360 LLC, a medical advisory firm offering services to pharmaceutical and biotechnology companies, is pleased to announce two Poster Presentations completed from the 2026 Tandem Meetings (Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR).
Medical Affairs 360 is pleased to announce that two poster presentations from Regimmune, a client partner, are now available for download from the 2026 Tandem Meetings.
The posters highlight the latest research and scientific insights in immune-oncology therapeutics in graft versus host disease, presented at the 2026 Annual ASTCT meeting, a leading scientific conference focused on blood and marrow transplantation and cellular therapy.
The posters provide detailed data and findings that contribute to ongoing scientific dialogue in the field, including one with cross trial comparison.
POSTER 1
Comparative Evaluation of Baseline Risk Factors and Acute GVHD Outcomes in Allogeneic Hematopoietic Cell Transplant (allo-HCT): RGI-2001 or Abatacept-Based Prophylaxis Studies presented by Phil Yeung, Pharm.D., explores the outcomes of FDA-approved Abatacept vs. RGI-2001, a novel invariant natural killer T (iNKT) cell agonist for aGVHD prophylaxis.
POSTER 2
Delayed Onset of Chronic GVHD in Patients Receiving RGI-2001Prophylaxis: A Multicenter Phase 2b Study with Comparison to CIBMTR Matched Cohort Data presented by Zachariah DeFilipp, MD, further explores delayed onset data of chronic GVHD from the Phase 2 study for RGI-2001.
“The Tandem Meetings placed a significant focus on clinical GVHD this year, introducing dedicated abstract categories for the first time to advance both prevention and treatment strategies,” said Dana Lee, Chief Clinical Development Officer at Medical Affairs 360. “We are excited to be at the forefront of sharing innovations in GVHD prevention and highlighting emerging research that aims to improve patient outcomes.”
“Medical Affairs 360 remains committed to supporting the dissemination of high-quality scientific information and facilitating access to important research presented at major medical congresses for our client partners” said Kenneth Tong, President and Founder of Medical Affairs 360 LLC.
About RGI-2001
RGI-2001, is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant NKT cells. It was discovered that a liposomal alpha-GalCer promotes tolerogenic immune cascade, resulting in the activation and expansion of Tregs. RGI-2001 has been evaluated for prevention of Graft-versus-Host Disease (GvHD) in patients undergoing HLA-matched allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematological malignancies. A Phase 2b study (NCT04014790) has completed the enrollment of 49 patients: RGI-2001 was well tolerated and demonstrated preliminary signs of efficacy.
About Regimmune, Inc.
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for rare diseases and cancer by leveraging underexploited biological opportunities. We specifically target well-characterized biological pathways with compelling scientific data supporting their importance in regulating the immune response against disease. For more information, please visit www.regimmune.com.
About Medical Affairs 360 LLC
Medical Affairs 360 is boutique medical advisory firm offering services to pharmaceutical and biotechnology companies. Our partnership services encompass strategic and clinical guidance from early research to full launch readiness and ongoing medical affairs activities. For more information, please visit www.medicalaffairs360.com.
Contacts
Kenneth Tong, President and Founder
Medical Affairs 360 LLC.
info@medicalaffairs360.com